Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patiromer to optimize mineralocorticoid receptor antagonist therapy in hyperkalaemic HFrEF
2017-003555-35Phase 4Completed
- Sponsor
- Fresenius Medical Care
- Start
- Oct 2017
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in heart failure with reduced ejection fraction (HFrEF) and hyperkalemia comparing Patiromer arm with Standard of care arm (2 arms). Started Oct 2017; status: completed.
02
Drugs
patiromer
03
Conditions
heart failure with reduced ejection fraction (HFrEF)hyperkalemia
Beyond the preview
Go deeper on 2017-003555-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003555-35.